Under the Paperwork Recoglion Act

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
no persons are required to respond to a collection of information unless it contains a valid OMB

control number.

Sheet

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known						
Application Number	10/510,658					
Filing Date	October 7, 2004					
First Named Inventor	Amanda Proudfoot					
Group Art Unit	1646					
Examiner Name	Prema Ment					
Attorney Docket Number	APS-104					

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	iner Cite Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the		T²			
PM R1		HEMMERICH, S. et al. "Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2", <i>Biochemistry</i> , October 5, 1999, pp. 13013-13025, Vol. 38, No. 40.				
	R2	STEITZ, S. A. et al. "Mapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesis", FEBS Letters, July 3, 1998, pp. 158-164, Vol. 430, No. 3.				
	R3	SEET, B. T. et al. "Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor", <i>Proceedings of the National Academy of Sciences of the United States</i> , July 31, 2001, pp. 9008-9013, Vol. 98, No. 16.				
	R4	MAYER, M. R. et al. "Identification of receptor binding and activation determinants in the N-terminal and N-loop regions of the CC chemokine eotaxin", Journal of Biological Chemistry, April 27, 2001, pp. 13911-13916, Vol. 276, No. 17.				
	R5	CHAKRAVARTY, L. et al. "Lysine 58 and histidine 66 at the C-terminal alpha-helix of monocyte chemoattractant protein-1 are essential for glycosaminoglycan binding", Journal of Biological Chemistry, November 6, 1998, pp. 29641-29647, Vol. 273, No. 45.				
	R6	DAWSON, J. et al. "Targeting monocyte chemoattractant protein-1 signaling in disease", Expert Opinion on Therapeutic Targets, February 2003, pp. 35-48, Vol. 7, No. 1.				
	R7					
	R8					
	R9					
	R10					
	R11					
	R12					

						-
Examiner Signature	Ruma	Ment	Date Considered	6	20	07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if rifet in conformance

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if riot in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.